Portopulmonary hypertension in cirrhosis: The pathogenetic challenge [2]

Gut

Volumn 54, Issue 2, 2005, Pages 309-

  Wong, F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR; INTERLEUKIN 6;

DISEASE ASSOCIATION; HUMAN; LETTER; LIVER CIRRHOSIS; LUNG CIRCULATION; LUNG PRESSURE; PATHOGENESIS; PORTAL HYPERTENSION; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; SPLANCHNIC BLOOD FLOW;

ENDOTHELIN-1; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LIVER CIRRHOSIS;

EID: 19944432529     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.051318     Document Type: Letter

References (7)

1. Vaughan RB, Angus PW, Chin-Dusting JPF. Evidence for altered vascular responses to exogenous endothelin-1 in patients with advanced cirrhosis with restoration of the normal vasoconstrictor response following successful liver transplantation. Gut 2003;52:1505-10.
2. Luo B, Liu L, Tang L, et al. Increased pulmonary vascular endothelin B receptor expression and responsiveness to endothelin-1 in cirrhotic and portal hypertensive rats: a potential mechanism in experimental hepotopulmonary syndrome. J Hepatol 2003;38:556-63.
3. Martinet JP, Legault L, Cernacek P, et al. Changes in plasma endothelin-1 and big endothelin 1 induced by transjugular intrahepatic portosystemic shunts in patients with cirrhosis and refractory ascites. J Hepatol 1996;25:700-6.
4. Nagasue N, Dahr DK, Yamanoi A, et al. Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis. Hepatology 2000;31:1107-14.
5. Gerbes A, Moller S, Gulberg V, et al. Endothelin-1 and 3 plasma concentrations in patients with cirrhosis: role of splanchnic and renal passage and liver function. Hepatology 1995;21:735-9.
6. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol 2001;115:3-12.
7. Streetz KL, Tacke F, Leifeld L, et al. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology 2003;38:218-29.